ImmunoCellular Therapeutics (OTCMKTS:IMUCD) is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of aggressive cancers. The company’s proprietary platform centers on dendritic cell vaccines designed to elicit a robust immune response against tumor-associated antigens, with an emphasis on eliminating cancer stem cells that drive tumor growth and recurrence. ImmunoCellular’s lead candidates have been evaluated in clinical trials for glioblastoma multiforme (GBM), a highly malignant form of brain cancer, and its pipeline includes additional programs targeting both primary and metastatic solid tumors.
ImmunoCellular’s most advanced product candidate, ICT-107, is an autologous dendritic cell vaccine engineered to present multiple tumor-associated antigens to the patient’s immune system. Early-stage clinical data have suggested potential improvements in progression-free survival for newly diagnosed GBM patients. The company is also advancing next-generation vaccine candidates that leverage refined antigen selection and adjuvant strategies to broaden the immune response and enhance durability. Manufacturing processes are conducted in compliance with current Good Manufacturing Practice (cGMP) standards, and the company collaborates with academic medical centers to conduct its clinical trials.
Founded in 2003 and headquartered in Southern California, ImmunoCellular has navigated multiple phases of clinical development, strategic alliances, and financing activities to support its research programs. The company’s management team comprises industry veterans in immuno-oncology, cell therapy manufacturing, and clinical trial operations. ImmunoCellular maintains facilities in the Los Angeles area for its research, development, and quality control functions, and its clinical trials enroll patients at leading cancer centers across the United States.
As a publicly traded entity on the OTC Markets, ImmunoCellular Therapeutics engages with investors, academic collaborators, and regulatory authorities to advance its mission of creating next-generation immunotherapies for hard-to-treat cancers. The company continues to explore partnerships and out-licensing opportunities to expand the global reach of its vaccine candidates while pursuing additional indications where its dendritic cell platform may offer therapeutic benefit.
AI Generated. May Contain Errors.
Free IMUCD Stock Alerts